secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-10-14T21:19:04+00:00
Accession:  0001193125-26-421820
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

FDA expands ANKTIVA plus BCG label to papillary-only BCG-unresponsive NMIBC, widening IBRX market
--------------------------------------------------------------------------------

- FDA expanded ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG to treat BCG-unresponsive NMIBC with papillary-only tumors; first approval for this population.
- Papillary disease is ~85% of NMIBC patients; NMIBC is ~80% of US bladder cancer diagnoses, materially expanding IBRX's US addressable population.
- QUILT-3.032 Cohort A: 62% of 77 patients achieved complete response (95% CI 51-73); 58% maintained response >=12 months, 40% >=24 months.
- Builds on April 2024 approval covering CIS with or without papillary tumors; label now covers all BCG-unresponsive NMIBC patients.
- Most common TRAEs were instillation-related (dysuria, pollakiuria, hematuria), mostly grade 1-2; label warns delaying cystectomy can risk metastatic disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312526421820/0001193125-26-421820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312526421820/d188887d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-421820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer